Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment - 29/05/26

Doi : 10.1016/j.tjpad.2026.100609

Elizabeth Kuhn ^a,^b,^⁎ , Luca Kleineidam ^a,^b , Melina Stark ^a,^b , Oliver Peters ^c,^d,^e , Julian Hellmann-Regen ^c,^d,^e , Lukas Preis ^d , Daria Gref ^c,^e , Josef Priller ^c,^f,^g,^h , Eike Jakob Spruth ^c,^f , Maria Gemenetzi ^c,^f , Anja Schneider ^a,^b , Klaus Fliessbach ^a,^b , Jens Wiltfang ^i,^j,^k , Claudia Bartels ⁱ , Niels Hansen ⁱ , Ayda Rostamzadeh ^l , Emrah Düzel ^m,ⁿ , Wenzel Glanz ^m , Enise Incesoy ^m , Katharina Buerger ^o,^p , Daniel Janowitz ^o,^p , Sophia Stöcklein ^o,^q , Robert Perneczky ^o,^r,^s,^t , Boris-Stephan Rauchmann ^r,^u,^v , Stefan J. Teipel ^w,^x , Ingo Kilimann ^w,^x , Christoph Laske ^y,^z , Sebastian Sodenkamp ^y,^aa , Annika Spottke ^a,^ab , Marie Kronmüller ^a , Sandra Roeske ^a , Frederic Brosseron ^a , Alfredo Ramirez ^a,^b,^ac,^ad,^ae , Matthis Synofzik ^af,^ag , Matthias C. Schmid ^a,^ah , Frank Jessen ^a,^l,^ac , Michael Wagner ^a,^b
for the
Alzheimer’s Disease Neuroimaging Initiative ^{^⁎}
Part of the data used in preparation of this article was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ( adni.loni.usc.edu ). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data, but they did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: ADNI_Acknowledgement_List.pdf . The ADNI was launched in 2003 as a public-private partnership led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD).

and the
DELCODE study group ^{^§}
The DELCODE study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)), reference number BN012 .

^a German Center for Neurodegenerative Diseases (DZNE) Bonn, Venusberg-Campus 1/99 53127, Bonn, Germany

^b Department of Cognitive Disorders and Old Age Psychiatry, University Hospital Bonn, Venusberg-Campus 1 53127, Bonn, Germany

^c German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany

^d Charité Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Hindenburgdamm 30 12203 Berlin, Germany

^e Charité Universitätsmedizin Berlin, ECRC Experimental and Clinical Research Center, Lindenberger Weg 80 13125 Berlin, Germany

^f Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1 10117 Berlin, Germany

^g Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, and German Center for Mental Health (DZPG), Munich, Germany

^h University of Edinburgh and UK DRI, Edinburgh, United Kingdom

ⁱ Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5 37075 Goettingen, Germany

^j German Center for Neurodegenerative Diseases (DZNE) Goettingen, Goettingen, Germany

^k Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal

^l Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62 50924, Cologne, Germany

^m German Center for Neurodegenerative Diseases (DZNE) Magdeburg, Magdeburg, Germany

ⁿ Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany

^o German Center for Neurodegenerative Diseases (DZNE) Munich, Feodor-Lynen-Strasse 17,81377 Munich, Germany

^p Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17 81377 Munich, Germany

^q Department of Radiology, Ludwig Maximilian University Hospital, Munich 81377, Germany

^r Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

^s Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany

^t Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, United Kingdom

^u Department of Neuroradiology, University Hospital, LMU Munich, Munich, Germany

^v Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom

^w German Center for Neurodegenerative Diseases (DZNE) Rostock, Rostock, Germany

^x Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20 18147 Rostock, Germany

^y German Center for Neurodegenerative Diseases (DZNE) Tuebingen, Tuebingen, Germany

^z Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany

^aa Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany

^ab Clinic for Parkinson's, Sleep and Movement Disorders, Centre for Neurology, University Hospital Bonn, Bonn, Germany

^ac Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Strasse 26 50931, Köln, Germany

^ad Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

^ae Department of Psychiatry & Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, San Antonio, TX, USA

^af German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

^ag Division of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany

^ah Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany

^⁎ Corresponding author at: German Center for Neurodegenerative Diseases (DZNE) Bonn, Venusberg-Campus 1/99 53127, Bonn, Germany. German Center for Neurodegenerative Diseases (DZNE) Bonn Venusberg-Campus 1/99 Bonn 53127 Germany

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

Subjective cognitive decline is common in older adults and may represent an early clinical signal along the Alzheimer’s disease continuum. The clinical relevance of longitudinal changes in subjective cognitive decline remains unclear.

Objectives

To determine whether trajectories of self- or study partner-reported cognitive decline predict progression to mild cognitive impairment and reflect Alzheimer’s disease-specific biological patterns.

Design, setting, participants

Data were pooled from two observational cohorts. Cognitively unimpaired participants with baseline amyloid status, repeated assessments of subjective cognitive decline, and clinical follow-up were included. The study included 770 participants with a median follow-up of 5.0 years (interquartile range 4.0–7.0).

Measurements

Subjective cognitive decline was assessed using the Everyday Cognition questionnaire completed by participants and study partners. Linear mixed-effects models examined associations with amyloid status and progression to mild cognitive impairment. Cox proportional hazards models tested whether one-year changes predicted progression.

Results

Amyloid-positive participants and those who progressed to mild cognitive impairment showed steeper increases in self- and study partner-reported cognitive difficulties over time. Among amyloid-positive participants, only increases in study partner-report differentiated progressors from non-progressors. One-year increases in study partner-report predicted a higher risk of mild cognitive impairment compared with unchanged scores (hazard ratio 3.24; 95% confidence interval 1.73–6.07]), with effects confined to amyloid-positive participants.

Conclusions

Short-term increases in study partner-reported cognitive difficulties identify amyloid-positive cognitively unimpaired older adults at increased risk of near-term progression to mild cognitive impairment. Longitudinal monitoring using study partner reports may provide a low-burden and clinically relevant approach for early risk stratification and surveillance in aging populations.

Le texte complet de cet article est disponible en PDF.

Keywords : Subjective cognitive decline, Study partner report, Self-report, Alzheimer’s pathology, Clinical progression

Abbreviations : Aβ , Aβ- , Aβ+ , AD , ADNI , APOE , CSF , CU , DELCODE , FBP , FTP , MCI , NA , NIA-AA , PET , SCD , SD , SUVr , T- , T+

Plan

Subjective cognitive decline assessments

Clinical progression to incident-MCI

Alzheimer’s disease biomarkers

Statistical analyses

Results

Participant characteristics

Longitudinal changes in Ecog reports

Risk of progression to MCI risk according to one-year Ecog changes

Complementary analyses

Discussion

Funding sources

Declaration of generative AI and AI-assisted technologies in the manuscript preparation process

CRediT authorship contribution statement

Export

Vol 13 - N° 8

Article 100609- octobre 2026 Retour au numéro

Article précédent

Mapping the nature, type, and association network of safety incidents among individuals with cognitive impairment in China: a large-scale multicenter cross-sectional study
Ying Zhou, Guoping Peng, Zhengluan Liao, Huayan Liu, Jun Liu, Wang Liao, Qiumin Qu, Jingping Shi, Jieli Geng, Nan Zhi, Wenwei Cao, Yaying Song, Yang Zhang, Xiaohong Wang, Lin Wang, Yuan Zhu, Yan Zhou, Huali Wang, Yongan Sun, Rujing Ren, Hengge Xie, Gang Wang, representing ADC

| Article suivant

Combined effect of anxiety disorder and insomnia on the risk of incident ADRD diagnosis
SangNam Ahn, Joanne Salas, Jinmyoung Cho, Jeffrey F. Scherrer

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment - 29/05/26

Abstract

Background

Objectives

Design, setting, participants

Measurements

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL